ImmunityBio, Inc. — Director's Dealing 2021

Aug 20, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ImmunityBio, Inc. (IBRX)
CIK: 0001326110
Period of Report: 2021-08-17

Reporting Person: Cohen Cheryl (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-17	Common Stock	S	43398	$10.124	Disposed	227527	Direct
2021-08-18	Common Stock	S	2133	$10.0277	Disposed	225394	Direct

Footnotes

F1: The sale of shares reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on May 13, 2021.

F2: Represents the weighted average share price of an aggregate total of 43,398 shares sold in the price range of $10.00 to $10.61 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F3: Represents the weighted average share price of an aggregate total of 2,133 shares sold in the price range of $10.00 to $10.05 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.